{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:26Z","timestamp":1790912486943,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Inviragen Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We report long-term safety and immunogenicity of Takeda\u2019s tetravalent dengue vaccine candidate (TAK-003) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore, and Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5\u201345 year olds (n\u2005=\u2005148) into 4 age-descending groups, randomized 2:1 to receive 2 doses of TAK-003 or placebo 90 days apart. In part 2, 1\u201311 year olds (n\u2005=\u2005212) were enrolled and randomized 3:1 to TAK-003 or placebo groups. We assessed neutralizing antibody titers for the 4 dengue serotypes (DENV) up to month 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to month 36 in both parts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At month 36, seropositivity rates were 97.3%, 98.7%, 88.0% and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositives versus 21.6% in seronegatives). No vaccine-related SAEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The trial demonstrated persistence of neutralizing antibody titers against TAK-003 over 3 years in children and adults living in dengue-endemic countries, with limited contribution from natural infection. TAK-003 was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT01511250<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa406","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T15:08:59Z","timestamp":1594480139000},"page":"1513-1520","source":"Crossref","is-referenced-by-count":17,"title":["Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study"],"prefix":"10.1093","volume":"225","author":[{"given":"Chukiat","family":"Sirivichayakul","sequence":"first","affiliation":[{"name":"Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Barranco-Santana","sequence":"additional","affiliation":[{"name":"CAIMED Center, Ponce School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s Esquil\u00edn","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kilbury","sequence":"additional","affiliation":[{"name":"Takeda Vaccines Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Raanan","sequence":"additional","affiliation":[{"name":"Takeda Vaccines Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[{"name":"Takeda Vaccines Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"2022050519471855100_CIT0001","author":"World Health Organization."},{"key":"2022050519471855100_CIT0002","author":"Centers for Disease Control and Prevention"},{"key":"2022050519471855100_CIT0003","doi-asserted-by":"crossref","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519471855100_CIT0004","author":"World Health Organization."},{"key":"2022050519471855100_CIT0005","volume-title":"Dengue fever","author":"Schaefer","year":"2018"},{"key":"2022050519471855100_CIT0006","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2022050519471855100_CIT0007","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"2022050519471855100_CIT0008","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"2022050519471855100_CIT0009","first-page":"457","article-title":"Dengue vaccine: WHO position paper\u2014September 2018","volume":"93","author":"World Health Organization.","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2022050519471855100_CIT0010","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1371\/journal.pntd.0001180","article-title":"Age-specificity of clinical dengue during primary and secondary infections","volume":"5","author":"Thai","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519471855100_CIT0011","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1201-9712(02)90072-X","article-title":"Effect of age on outcome of secondary dengue 2 infections","volume":"6","author":"Guzm\u00e1n","year":"2002","journal-title":"Int J Infect Dis"},{"key":"2022050519471855100_CIT0012","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519471855100_CIT0013","article-title":"Dengue virus vaccine development: study on biological markers of uncloned dengue 1\u20134 viruses serially passaged in primary kidney cells","volume-title":"St. George TD, Kay BH, Blok J, eds. Arbovirus","author":"Yoksan","year":"1986"},{"key":"2022050519471855100_CIT0014","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"key":"2022050519471855100_CIT0015","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"2022050519471855100_CIT0016","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"2022050519471855100_CIT0017","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"2022050519471855100_CIT0018","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in Flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"2022050519471855100_CIT0019","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022050519471855100_CIT0020","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"2022050519471855100_CIT0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022050519471855100_CIT0022","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"Saez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022050519471855100_CIT0023","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa406\/33667157\/jiaa406.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1513\/43546289\/jiaa406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1513\/43546289\/jiaa406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:30:10Z","timestamp":1651768210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/9\/1513\/5870825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,13]]},"published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa406","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2020,7,13]]}}}